2025 Volume 51 Issue 4 Pages 696-703
We examined the effects of galcanezumab in migraine patients using a headache graph developed by our own quantitative evaluation method. The headache graph was calculated as the Headache Volume (HV) for one month by using a line graph with 11 levels of VAS on the vertical axis and the area bounded by a baseline line with input every 5 hours per day on the horizontal axis. In 23 migraine patients (M: F＝4:19, age 46. 2±10. 2, EM17, CM6) who received galcanezumab, the HV values for 3 months before and 6 months after administration were compared, and the mean HV values were significantly improved and maintained for 6 months from baseline. The frequency, intensity, and duration of pain were also significantly reduced after administration. The HV value of the headache graph visualized the intensity of the headache and the course of time without omission, enabling a more precise quantitative evaluation, and demonstrating the effectiveness of galcanezumab.
